Pembrolizumab Plus Platinum-Doublet Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Unresectable, Locally Advanced Stage III NSCLC: The KEYNOTE-799 Trial in Perspective

Cigarette Sales Up in U.S. for the First Time in 20 Years

Intratumoral Dendritic Cells in Treatment of Lung Cancer

New Warranty, Rebate Programs Put Spotlight on Value in Lung Cancer

Comprehensive Analysis of Proteomics Identifies New, Druggable Drivers of NSCLC—and New Avenue for Continued Research

Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%

The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer

First New Second-line Therapy for SCLC in Australia in 20 Years

Sotorasib Scores Second-line Approval in Canada

Question Literature’s Face Value

Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12 Study

Telehealth Struggles to Find Permanent Footing After Rapid Growth During Pandemic